Outset Medical (NASDAQ:OM) CFO Renee Gaeta Sells 17,672 Shares

Outset Medical, Inc. (NASDAQ:OM) CFO Renee Gaeta sold 17,672 shares of Outset Medical stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at approximately $561,939.82. The trade was a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Performance

NASDAQ:OM opened at $4.58 on Friday. The stock has a market cap of $84.91 million, a P/E ratio of -1.10 and a beta of 1.95. The stock has a 50 day simple moving average of $4.26 and a 200 day simple moving average of $4.17. The company has a current ratio of 6.29, a quick ratio of 4.97 and a debt-to-equity ratio of 0.87. Outset Medical, Inc. has a 1-year low of $3.00 and a 1-year high of $21.98.

Outset Medical (NASDAQ:OM) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The firm had revenue of $27.86 million for the quarter, compared to analyst estimates of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. Research analysts anticipate that Outset Medical, Inc. will post -3.82 earnings per share for the current year.

Hedge Funds Weigh In On Outset Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC acquired a new position in Outset Medical in the 4th quarter valued at $29,000. Legal & General Group Plc bought a new position in shares of Outset Medical in the 2nd quarter valued at $34,000. BNP Paribas Financial Markets increased its stake in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Outset Medical in the 4th quarter valued at $46,000. Finally, HRT Financial LP bought a new position in shares of Outset Medical in the 4th quarter valued at $58,000.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. BTIG Research dropped their price objective on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Friday, March 27th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Finally, Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Outset Medical currently has an average rating of “Hold” and an average price target of $10.00.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.